Top

Published in:

01-11-2010 | Letter

High-quality clinical practice: laparoscopic rectal cancer resection

Authors: Georgios Baltogiannis, Christos Katsios

Published in: Surgical Endoscopy | Issue 11/2010

Excerpt

Modern current and emerging technology and scientific expertise drive the outcomes of patients with potentially curable, nonmetastatic solid cancer. Despite advances in multimodal therapeutics, current failure rates in both locoregional and distant systemic treatment remain alarmingly high resulting in the death of most patients with advanced colorectal cancer. …

Cheung YM, Lange MM, Buunen M, Lange JF (2009) Current technique of laparoscopic total mesorectal excision (TME): an international questionnaire among 368 surgeons. Surg Endosc 23:2796–2801CrossRef

Poon JT, Law WL (2009) Laparoscopic resection for rectal cancer: a review. Ann Surg Oncol 16(11):3038–3047CrossRefPubMed

Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249(4):695–696CrossRefPubMed

Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22(5):1405–1406CrossRefPubMed

Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250(2):349–350CrossRefPubMed

Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22(6):1553–1555CrossRefPubMed

Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651CrossRef

Briasoulis E, Fatouros M, Roukos D (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695CrossRefPubMed

Roukos DH (2002) Adjuvant chemoradiotherapy in gastric cancer: wave goodbye to extensive surgery? Ann Surg Oncol 9:220–221CrossRefPubMed

10.

Briasoulis E, Liakakos T, Dova L, Fatouros M, Tsekeris P, Roukos DH, Kappas AM (2006) Selecting a specific pre- or postoperative adjuvant therapy for individual patients with operable gastric cancer. Expert Rev Anticancer Ther 6:931–939CrossRefPubMed

11.

Roukos DH (2009) Assessing both genetic variation (SNPs/CNVs) and gene–environment interactions may lead to personalized gastric cancer prevention. Expert Rev Mol Diagn 9(1):1–6CrossRefPubMed

12.

Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798CrossRefPubMed

13.

Roukos DH, Hottenrott C, Encke A, Baltogiannis G, Casioumis D (1994) Primary gastric lymphomas: a clinicopathologic study with literature review. Surg Oncol 3(2):115–125CrossRefPubMed

14.

Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726CrossRefPubMed

15.

Ziogas D, Roukos DH (2009) CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 16(10):2678–2681CrossRefPubMed

16.

Ziogas D, Baltogiannis G, Fatouros M, Roukos DH (2008) Identifying and preventing high-risk gastric cancer individuals with CDH1 mutations. Ann Surg 247(4):714–715CrossRefPubMed

17.

Roukos DH (2009) Isolated tumor cells in breast cancer. N Engl J Med 361:1994–1995CrossRefPubMed

18.

Roukos DH, Tzakos A, Zografos G (2009) Current concerns and challenges towards tailored antiangiogenic therapy in cancer. Expert Rev Anticancer Ther 9(10):1413–1416CrossRefPubMed

19.

Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068CrossRefPubMed

20.

Roukos DH (2009) Personalized cancer diagnostics and therapeutics. Expert Rev Mol Diagn 9(3):227–229CrossRefPubMed

21.

Roukos DH (2009) Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev Anticancer Ther 9(4):389–392CrossRefPubMed

22.

Roukos DH (2009) Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 27(8):1337–1338CrossRefPubMed

23.

Roukos DH (2009) Radiation therapy for breast cancer. N Engl J Med 360(13):1362 (author’s reply 1363)CrossRefPubMed

24.

Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773CrossRefPubMed

25.

Roukos DH, Ziogas D (2009) Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the “Gordian Knot”? Ann Surg Oncol 16(3):774–775CrossRefPubMed

26.

Roukos DH (2008) Breast-cancer stromal cells with TP53 mutations. N Engl J Med 358(15):1636PubMed

27.

Roukos DH (2009) Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 9(3):217–221CrossRefPubMed

28.

Roukos DH (2010) Novel clinico-genome network modeling for revolutionizing genotype–phenotype based personalized cancer care. Expert Rev Mol Diagn 10(1):33–48CrossRefPubMed

29.

Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128CrossRefPubMed

30.

Ziogas D, Roukos DH (2009) Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann Surg Oncol 16(7):1771–1782CrossRefPubMed

31.

Roukos DH (2008) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358(2):197; author reply 198CrossRefPubMed

32.

Roukos DH, Briasoulis E (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4:578–590CrossRefPubMed

33.

Roukos DH (2010) Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 11(3):283–287CrossRefPubMed

34.

Roukos DH (2010) Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 17:14–17CrossRefPubMed

Title: High-quality clinical practice: laparoscopic rectal cancer resection
Authors: Georgios Baltogiannis
Christos Katsios
Publication date: 01-11-2010
Publisher: Springer-Verlag
Published in: Surgical Endoscopy / Issue 11/2010
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI: https://doi.org/10.1007/s00464-010-1019-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

High-quality clinical practice: laparoscopic rectal cancer resection

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2010

Guidelines for surgical treatment of gastroesophageal reflux disease

Natural orifice transtracheal evaluation of the thoracic cavity and mediastinum

Initiation of a pediatric robotic surgery program: institutional challenges and realistic outcomes

Predictive factors for local recurrence after endoscopic resection for early gastric cancer: long-term clinical outcome in a single-center experience

Laparoscopy as a diagnostic and therapeutic option in evaluating chronic unexplained right iliac fossa pain

The feasibility of solo-surgeon living donor nephrectomy: initial experience using video-assisted minilaparotomy surgery